BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26749043)

  • 1. Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.
    Low AS; Lunt M; Mercer LK; Watson KD; Dixon WG; Symmons DP; Hyrich KL
    Arthritis Rheumatol; 2016 Jun; 68(6):1337-45. PubMed ID: 26749043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
    Low AS; Symmons DP; Lunt M; Mercer LK; Gale CP; Watson KD; Dixon WG; Hyrich KL;
    Ann Rheum Dis; 2017 Apr; 76(4):654-660. PubMed ID: 28073800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
    Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register.
    Rudi T; Zietemann V; Meissner Y; Zink A; Krause A; Lorenz HM; Kneitz C; Schaefer M; Strangfeld A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
    Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
    Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bechman K; Halai K; Yates M; Norton S; Cope AP; ; Hyrich KL; Galloway JB
    Arthritis Rheumatol; 2021 Oct; 73(10):1800-1809. PubMed ID: 33844458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Hyrich KL; ; Silman AJ; Symmons DP;
    Arthritis Rheum; 2007 Sep; 56(9):2905-12. PubMed ID: 17763428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.